# US 2012/0252734 A1 · Inhibitors of antigen presentation by mhc class ii molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252734 A1
- Document ID: US20120252734A1
- Status: Published application
- Kind: A1
- Application number: 13/523,960
- Filed: 2012-06-15
- Published: 2012-10-04
- Earliest claimed: 2003-02-14
- Assignees: Provid Pharmaceuticals, Inc.
- Inventors: Gary Lee Olson; Charles Michael Cook; Christopher Raymond Self
- Web page: https://patentgrep.com/patent/US20120252734A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

## Claims

### Claim 1

A compound, wherein the compound is:
ENPVVHFFKNI;
AcVHFFKNI;
AcIHFFKNI;
AcVRFFKNI;
AcVHPFKNI;
AcVHFFPNI;
AcVHFFKTI;
AcVRFANI;
AcVRPFS;
AcVRLFANI;
AcVVHFFKNI;
AcVTFFKNI;
AcVH(N-Me Ala)FKNI;
AcVHA(N-Me Ala)-F—(N-Me Ala)N;
AcVHFVKNI;
AcVRF(2-NaI)KNI;
AcVRF(1-NaI)KNI;
AcVHFFA(N-Me Ala)NI;
AcVRLFKN;
AcVRF(4′-Pyridyl Ala)KNI;
AcVRAFAN;
AcVRA(O-Benzyl Ser)KNI;
Ac(Tic)FKNI;
AcVR(Tic)FKNI;
Ac(Cpg)RFFKNI;
AcVHSFSN;
AcVRF(3′ Cyano Phe)KNI;
AcVR(Tiq)FKNI;
Ac(Tiq)FKNI;
AcVVRFFK;
AcVRFF(homo Pro)NI;
Ac(Tic)FKNI;
Ac(Cpg)R(Tic)FKNI;
AcVR(homo Pro)FKNI;
AcVRFFK;
AcVKFFKNI;
AcV(Orn)FFKNI;
AcV(N′ Alloc Dab)FFKNI;
Ac(Cha)RFFKNI;
Ac(2′ Furanyl Ala)RFFKNI;
Ac(2′ Thienyl Ala)RFFKNI;
AcVR(2′ Furanyl Ala)FKNI;
AcVR(2′ Thienyl Ala)FKNI;
AcVRAFKNI;
Benzoyl-VRFFK;
Isobutanoyl-VRFFK;
Butanoyl-VRFFK;
IsoValeroyl-VRFFK;
Ac(Cpg)R(Tic)F(homo Pro);
AcVVRFF;
3-(Imadazoyl-4-yl)propionyl-VRFFK;
Ac(Chg)RFFKNI;
AcVRFF(Dap)NI;
AcV(Dab)FFKNI;
AcVVAGFKNI;
AcVAGFKNI;
AcV(Dap)FFKNI;
AcVRFF;
AcVRF(3′ phenoxy Phe)KNI;
AcVVKF(3′ Methylamino Phe) K;
AcFRFFKNI;
AcVRFFK(beta Ala)I;
AcV('-amino-1′-carboxymethyl-pyridin-2′-one)FKNI;
Ac(Idg)RFFKNI;
AcAVRFFK;
AcAVHFFKNI;
AcV(2′ Furanyl Ala)FFKNI;
AcV(2′ Thienyl Ala)FFKNI;
AcVVKF(3′ Cyano Phe)K;
Ac(Phg)RFFKNI;
AcIR(Tic)F(homo Pro);
AcLRFFKNI;
AcVR(Phg)FKNI;
AcVVRF(3′ phenoxy Phe)K;
AcVRF(Phg)KNI;
AcVRFFK(beta Ala);
AcVVRFFK(beta Ala);
Ac(Chg)VRFFK;
Ac(Chg)RF(4′-Indolyl Ala)KNI
AcVRF(3′-Carbazolyl Ala)KNI;
Ac(Cpg)-NHNH(COCH2CH(Ph)CO)KNI;
AcVRF(3′-amino Phe)KNI;
AcWRFFKNI;
AcV(ω, ω) dimethyl Lys)FFKNI;
AcV(Chg)RFFK;
AcV(nor Arg)FFKNI;
AcVRF(3-Acetylamino Phe)KNI;
Ac(Chg)R(Tic)F(4′-hydroxy Pro);
Ac(Chg)R(Tic);
AcVKFFENI;
AcVRIFKNI;
Ac(Cpg)-NHNH(COCH2CH(Ph)CO)FKNI;
Ac(Chg)R(Tic)-(3′-Carbazolyl Ala);
Ac(Chg)R(Tic)F(homo Pro);
Ac(Idg)R(Tic)FK;
AcV(Idg)R(Tic)FK;
AcV(Chg)R(Tic)F;
AcV(Chg)RFFK;
Ac(Chg)R(Tic)-(3′-Carbazolyl Ala)G;
AcV(Chg)R(Tic)-(3′-Carbazolyl Ala)G;
AcVVRF(3′-Acetylaminomethyl Phe);
AcVVRF(3′-Methylsulphonyl aminomethyl Phe);
(2,6-Dimethyl Benzoyl)-VRFFK;
AcV(homo Arg)FFKNI;
Ac(Cpg)-NHNH(COCH2CH(Ph)CO)-(4′-Indolyl Ala)K;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is AcV(Chg)R(Tic)F, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, comprising AcV(Chg)R(Tic)F, and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, suitable for subcutaneous administration.

### Claim 6 (depends on 1)

A method for treating an autoimmune disease responsive to the inhibition of antigen binding to a MHC class II molecule, comprising administering to a patient having an autoimmune disease responsive to the inhibition of antigen binding to a MHC class II molecule a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound is AcV(Chg)R(Tic)F, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the autoimmune disease is multiple sclerosis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the patient is a human.

### Claim 10 (depends on 9)

The method of claim 9, wherein the route of administration of the compound is subcutaneous.

### Claim 11 (depends on 1)

A method for treating an autoimmune disease responsive to the inhibition of antigen presentation by a MHC class II molecule, comprising administering to a patient having an autoimmune disease responsive to the inhibition of antigen presentation by a MHC class II molecule a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the compound is AcV(Chg)R(Tic)F, or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the autoimmune disease is multiple sclerosis.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient is a human.

### Claim 15 (depends on 14)

The method of claim 14, wherein the route of administration of the compound is subcutaneous.

### Claim 16 (depends on 1)

A method for treating an autoimmune disease comprising administering to a patient having an autoimmune disease a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound is AcV(Chg)R(Tic)F, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the autoimmune disease is multiple sclerosis.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient is a human.

### Claim 20 (depends on 19)

The method of claim 19, wherein the route of administration of the compound is subcutaneous.
